Building Public Trust Awards - Highly Commended

RNS Number : 1207S

Hikma Pharmaceuticals Plc

27 November 2012

 



PRESS RELEASE                                                                   

Hikma Highly Commended - Building Public Trust Awards

London, 27 November 2012 - Hikma Pharmaceuticals PLC (LSE: HIK) (NASDAQ Dubai: HIK) ("Hikma"), the fast growing multinational pharmaceutical group, is very pleased to announce that it has been "Highly Commended" for its remuneration disclosure in the 2011 annual report and accounts by the Building Public Trust Awards.

The judges commented:

"Hikma's report was differentiated from others by its unusual design and eye-catching layout. The report includes a number of interesting features, including a consistent approach to explain elements of remuneration by reference to desired and actual benchmarks, together with detailed disclosure of the total compensation paid to all directors for the year and the current performance of the outstanding LTIP awards."

The judges were looking for disclosure of directors' remuneration that met three key criteria:

• A manifest commitment by the remuneration committee to best practice reporting;

• Clear communication of how incentive plans drive the right behaviours in the executive team through alignment with business strategy and the interests of stakeholders; and

• Adoption of the changes foreshadowed in the consultation

-----  ENDS -----

Enquiries

Hikma Pharmaceuticals PLC

Peter Speirs, Company Secretary                                 [phone]

About Hikma

Hikma Pharmaceuticals PLC is a fast growing multinational pharmaceutical group focused on developing, manufacturing and marketing a broad range of both branded and non‐branded generic and in‐licensed products. Hikma's operations are conducted through three businesses: "Branded", "Injectables" and "Generics" based principally in the Middle East and North Africa ("MENA") region, where it is a market leader, the United States and Europe. In 2011, Hikma achieved revenue of $918.0 million and profit attributable to shareholders of $80.1 million.

 

END

 

 

MSCDMMZMFNZGZZM